Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-PEDS1: Lasmiditan for Acute Treatment of Migraine in Children and Adolescents
2023-506253-38-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing High-dose lasmiditan with Placebo (2 arms). Primary endpoint: Pain freedom (high dose). Started Mar 2024; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2023-506253-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506253-38-00.